Dermatomiositis juvenil y calcinosis extensa. Tratamiento con metilprednisolona y metotrexato

Ayala, Zoilo Morel; Ramírez, Rogelio Martínez; Zerón, Samara Mendieta; Fuentes, Enrique Faugier; Velázquez, Rocío Maldonado

doi:10.1016/s1699-258x(08)75546-3

Reumatología Clínica

2008

DOI: 10.1016/s1699-258x(08)75546-3

|View full text |Cite

Dermatomiositis juvenil y calcinosis extensa. Tratamiento con metilprednisolona y metotrexato

Zoilo Morel Ayala¹,

Rogelio Martínez Ramírez²,

Samara Mendieta Zerón³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2023

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 Calcinosis in JDM patients can cause more incapacity and complications than the myopathy itself. 2 Soft tissue calcification can be anywhere, including superficial skin (calcinosis cutis), around joints (calcinosis circumscripta) or deep fascial planes (calcinosis universalis).…”

mentioning

confidence: 99%

Calcinosis Universalis in Juvenile Dermatomyositis

Chung

2020

Chonnam Med J

View full text Add to dashboard Cite

mentioning

confidence: 99%

Calcinosis Universalis in Juvenile Dermatomyositis

Chung

2020

Chonnam Med J

View full text Add to dashboard Cite

Calcinosis in Juvenile Dermatomyositis—Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review

Gonçalves Júnior,

Shinjo

2023

Curr Rheumatol Rep

View full text Add to dashboard Cite

Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review

Mainetti

Beretta‐Piccoli

Selmi

2017

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by the presence of skin lesions and inflammation of skeletal muscles; however, this feature may be absent in amyopathic DM. DM is a rare disease, occurring at any age, and has two peaks of incidence: one in childhood between 5 and 15 years of age and one in adulthood between 40 and 60 years, with a female preponderance. DM has been associated with malignancy; therefore, every newly diagnosed patient should undergo screening investigations, but evidence-based guidelines on their extension are lacking. The etiopathogenesis is still unclear, but a range of factors such as genetic predisposition, environment triggers, and immune- and non-immune-mediated mechanisms play a role in the development of the disorder. Some dermatological findings and new discoveries on immunological mechanisms in DM, including the association of certain autoantibodies with cancer, can be helpful in clinical practice. Therapy should consider both skin and muscle or internal organ involvement. Photoprotection, including the use of antimalarial drugs, plays an important role in the therapeutic approach of skin involvement. Treatment of muscle and internal organ involvement is based on systemic corticosteroids, alone or in association with disease-modifying antirheumatic drugs. Intravenous immunoglobulins have been demonstrated to be effective as second-line therapy. Rituximab is an emerging treatment for difficult-to-treat DM, both in adults and children. In this review article, we discuss DM subforms, focusing on their dermatological manifestations that can be classified as pathognomonic, characteristic, compatible, less common, rare, recently-described, and non-specific skin lesions.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Dermatomiositis juvenil y calcinosis extensa. Tratamiento con metilprednisolona y metotrexato

Cited by 4 publications

References 10 publications

Calcinosis Universalis in Juvenile Dermatomyositis

Calcinosis Universalis in Juvenile Dermatomyositis

Calcinosis in Juvenile Dermatomyositis—Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review

Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review

Contact Info

Product

Resources

About